The proxy reveals extreme potential dilution (up to 293% of current shares) from two separate convertible preferred issuances, combined with a reverse split proposal to address Nasdaq delisting risk. Monitor the vote outcome on Proposals 5, 6 and 7; if all pass, existing holders face massive dilution. The reincorporation to Nevada (Proposal 9) is a cost-saving measure but changes director liability standards. The auditor change and going concern opinion signal continued financial distress.
Price Chart
Executive Summary
Vivos Therapeutics filed its definitive proxy statement for the 2026 Annual Meeting, seeking shareholder approval on 10 proposals including a reverse stock split (1-for-20 to 1-for-40) to regain Nasdaq bid-price compliance, approval of massive potential share issuances to New Seneca Partners (up to 18.5M shares) and SOD Sciences (up to 80M shares), a 4.9M share increase to the equity plan, and a reincorporation from Delaware to Nevada to reduce franchise tax costs. The filing reveals a micro-cap company with a $4M market cap, widening net losses ($21.2M in 2025 vs $11.1M in 2024), negative compensation actually paid to the CEO, and substantial dilution risk from existing convertible securities.
Key Facts
- Company received Nasdaq deficiency notice on June 5, 2026 for failing $1.00 minimum bid price; compliance period runs to December 2, 2026
- Proposal 5 seeks reverse stock split at ratio of 1-for-20 to 1-for-40 to regain bid price compliance
- Proposal 6 seeks approval to issue up to 18,476,959 shares (55% of outstanding) upon conversion/exercise of Series A Preferred and warrants held by New Seneca Partners and affiliates
- Proposal 7 seeks approval to issue up to 80,000,000 shares (238% of outstanding) upon conversion of Series C Preferred issued to SOD Sciences at $0.15 per share
- Proposal 8 seeks to increase equity plan share reserve by 4,900,000 shares (from 4,100,000 to 9,000,000)
- Proposal 9 seeks reincorporation from Delaware to Nevada to reduce franchise tax costs
- Consolidated net loss widened to $21.2 million in 2025 from $11.1 million in 2024
- CEO R. Kirk Huntsman total compensation was $511,084 in 2025; compensation actually paid was negative ($239,036) due to equity value decline
- Former CFO Bradford Amman resigned July 31, 2026; received separation package including 250,000 fully vested shares and option for 150,000 shares
- New CFO Roman Franklin serves via CFO Portal LLC at $27,000/month retainer ($324,000 annually) plus option for 552,000 shares
- Baker Tilly US, LLP dismissed as auditor; Haynie & Company appointed for FY2026
- Baker Tilly's 2025 audit report included going concern explanatory paragraph
- Two 5% holders (New Seneca Partners group and SOD Sciences) each reported at 19.99% beneficial ownership cap
- Market cap is approximately $4M with 33,609,393 shares outstanding as of record date
Financial Impact
Potential dilution of up to 98.5 million new shares (293% of current outstanding) if Proposals 6 and 7 are approved; net loss of $21.2 million in 2025; CEO total compensation $511,084; audit fees $868,000 in 2025
Risk Factors
- Nasdaq delisting risk if reverse split not approved or fails to maintain $1.00 bid price
- Extreme dilution from up to 98.5 million potential new shares if Proposals 6 and 7 are approved
- Going concern risk as losses widen ($21.2M in 2025) and market cap is only $4M
- CEO indirectly participated in June 2026 private placement creating conflict of interest on Proposal 6
- Multiple late Section 16 filings indicate weak internal controls over reporting
- Auditor change and increased audit fees ($868K vs $362K) suggest heightened scrutiny
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001493152-26-049258 |
| Document: 0001493152-26-049258-index-headers.html | 0001493152-26-049258 |
| Document: 0001493152-26-049258-index.html | 0001493152-26-049258 |
| Document: 0001493152-26-049258.txt | 0001493152-26-049258 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | DEF 14A | $0.1206 | awaiting T+60 | awaiting T+60 | $0.1140 (+5.47%) |
Oct 21, 2026 11d ago | 8-K | $0.1347 | awaiting T+60 | awaiting T+60 | $0.1140 (−15.37%) |
Oct 19, 2026 13d ago | Press Release | $0.1410 | awaiting T+60 | awaiting T+60 | $0.1140 (−19.15%) |
Oct 19, 2026 13d ago | 8-K | $0.1406 | awaiting T+60 | awaiting T+60 | $0.1140 (−18.92%) |
Oct 15, 2026 17d ago | 8-K | $0.1428 | awaiting T+60 | awaiting T+60 | $0.1140 (−20.17%) |
Oct 15, 2026 17d ago | Press Release | $0.1428 | awaiting T+60 | awaiting T+60 | $0.1140 (−20.17%) |
Sep 30, 2026 4w ago | 8-K | $0.1490 | awaiting T+60 | awaiting T+60 | $0.1140 (+23.49%) |
Aug 28, 2026 9w ago | Press Release | $0.2249 | awaiting T+60 | awaiting T+60 | $0.1140 (−49.31%) |
Aug 21, 2026 10w ago | 8-K | $0.2768 | awaiting T+60 | awaiting T+60 | $0.1140 (−58.82%) |
Aug 14, 2026 11w ago | Press Release | $0.3012 | awaiting T+60 | awaiting T+60 | $0.1140 (+62.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers